Can-Fite BioPharma (CANF) Return on Capital Employed (2015 - 2023)
Can-Fite BioPharma's (CANF) quarterly Return on Capital Employed came in at 108.41% in Q4 2023, down 1192.0% YoY from 9.93% in Q4 2022, and down 13.41% on a QoQ basis from 95.6% in Q3 2023.
Can-Fite BioPharma (CANF) Return on Capital Employed (2015 - 2023) Analysis & Trends
Can-Fite BioPharma (CANF) has 9 years of Return on Capital Employed data on file, last reported at 108.41% in Q4 2023.
- Quarterly Return on Capital Employed fell 1192.0% year-over-year to 108.41% in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 108.41% (down 1192.0% YoY) and the FY2025 annual result came in at 151.08%, down 4271.0% from the prior year.
- Return on Capital Employed slipped to 108.41% in Q4 2023, from 95.6% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 80.77% in Q1 2022 to a low of 179.44% in Q4 2019.
- A 5-year average of 108.77% and a median of 100.75% in 2022 frame the typical range for Return on Capital Employed.
- The widest YoY moves for Return on Capital Employed: up 10653 bps in 2019, down 9308 bps in 2019.
- Tracing CANF's Return on Capital Employed over 5 years: stood at 179.44% in 2019, then advanced by 22 bps to 139.23% in 2020, then jumped by 37 bps to 87.27% in 2021, then dropped by 11 bps to 96.5% in 2022, then slipped by 12 bps to 108.41% in 2023.
- The last three Return on Capital Employed figures came in at 108.41% (Q4 2023), 95.6% (Q3 2023), and 82.28% (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | Can-Fite BioPharma | 2.82 Mn | -8.73 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -108.41% |
| Sep 30, 2023 | -95.60% |
| Jun 30, 2023 | -82.28% |
| Mar 31, 2023 | -100.49% |
| Dec 31, 2022 | -96.50% |
| Sep 30, 2022 | -101.02% |
| Jun 30, 2022 | -84.69% |
| Mar 31, 2022 | -80.77% |
| Dec 31, 2021 | -87.27% |
| Sep 30, 2021 | -123.59% |
| Jun 30, 2021 | -128.06% |
| Mar 31, 2021 | -132.63% |
| Dec 31, 2020 | -139.23% |
| Dec 31, 2019 | -179.44% |
| Sep 30, 2019 | -103.29% |
| Jun 30, 2019 | -97.06% |
| Dec 31, 2018 | -86.35% |
| Sep 30, 2018 | -175.68% |
| Jun 30, 2018 | -203.59% |
| Mar 31, 2018 | -75.99% |